Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.14, 2018 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 14
- Publication Date: 2018
- Doi Number: 10.4103/0973-1482.235355
- Journal Name: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Keywords: Arylesterase, breast cancer, cancer risk, cut-off value, neoadjuvant, paraoxonase, screening, BODY-MASS INDEX, COLORECTAL-CANCER, OXIDATIVE STRESS, CARCINOGENESIS, INFLAMMATION, POLYMORPHISM, RADICALS, PON1, RISK
- Istanbul University Affiliated: Yes
Abstract
Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.